BiomX: BX004 Phage Cocktail Part 2, Phase 1b/2a Clinical Results In Cystic Fibrosis Expected Any Day
BiomX announced positive results from Part 1 of its Phase 1b/2a study for its novel phage cocktail, BX004, treating chronic pulmonary infections caused by P. aeruginosa bacteria in Cystic Fibrosis.
Premier research journal article provides validation for BiomX’s phage therapy platform, showcasing first-in-human Phase 1b/2a trial results for antibiotic-resistant P. aeruginosa infectionsNew, ...
NESS ZIONA, Israel, July 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results